IQVIA™ Real-World Insights Bibliography

Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Author(s): Avraham Karasik (1), Stefanie Lanzinger (2,3), Elise Chia-Hui Tan (4), Daisuke Yabe (5,6,7 8), Dae Jung Kim (9), Wayne H-H Sheu (10), Cheli Melzer-Cohen (1), Reinhard W. Holl (2), Kyoung-Hwa Ha (9), Kamlesh Khunti (11), Francesco Zaccardi (11), Anuradhaa Subramanian (12), Krishnarajah Nirantharakumar (12,13,14), Thomas Nyström (15), Leo Niskanen (16), Majken Linnemann Jensen (17), Fabian Hoti (18), Riho Klement (19), Anouk Déruaz-Luyet (20), Moe H.Kyaw (21), Lisette Koeneman (22), Dorte Vistisen (23, 24) Bendix Carstensen (23), Sigrun Halvorsen (25), Gisle Langslet (26), Soulmaz Fazeli Farsani (20), Elisabetta Patorno (27), Júlio Núñez (28), EMPRISE Europe and Asia Study Group
Affiliations(s): "1 Maccabi Institute for Research and Innovation Center, Tel Aviv University, Tel Aviv, Israel 2 Institute for Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany 3 German Centre for Diabetes Research (DZD), München-Neuherberg, Germany 4 Department of Health Service Administration, China Medical University, Taichung, Taiwan 5 Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kyoto, Japan 6 Department of Diabetes, Metabolism and Endocrinology/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan 7 Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan 8 Preemptive Food Research Center, Gifu University Institute for Advanced Study, Gifu, Japan 9 Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea 10 Division of Endocrinology and Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan 11 Leicester Real World Evidence Unit, Leicester Diabetes Centre, University of Leicester, Leicester, UK 12 Institute of Applied Health Research, University of Birmingham, Birmingham, UK 13 Midlands Health Data Research UK, Birmingham, UK 14 DEMAND Hub, University of Birmingham, Birmingham, UK 15 Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sweden 16 Päijät-Häme Joint Authority for Health and Wellbeing, Päijät-Häme Central Hospital, Lahti Finland and University of Eastern Finland, Kuopio, Finland 17 IQVIA Solutions Denmark A/S, Copenhagen, Denmark 18 IQVIA, Espoo, Finland 19 IQVIA, Tartu, Estonia 20 Boehringer Ingelheim International GmbH, Ingelheim, Germany 21 Boehringer Ingelheim International GmbH, US 22 Lilly Deutschland GmbH, Bad Homburg, Germany 23 Steno Diabetes Center Copenhagen, Herlev, Denmark 24 Department of Public Health, University of Copenhagen, Copenhagen, Denmark 25 Department of Cardiology, Oslo University Hospital Ullevål, and University of Oslo, Oslo, Norway 26 Lipid Clinic, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway 27 Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA 28 Department of Cardiology, Hospital Clínico Universitario de Valencia, INCLIVA, Universidad de Valencia, CIBER Cardiovascular, Valencia, Spain"
Publication(s):  "Diabetes & Metabolism. 2023 Jan; 101418; ISSN 1262-3636 Virtual Conference: American Diabetes Association, 25-29 June 2021 and EASD 27 September -01 October"
Document Type(s): Article,
Countries: Denmark, Finland, Germany, Norway, Spain, Sweden, UK,
Click here for the abstract
C:
Y:
Cardiovascular disease, Diabetes, Drug safety, Drug Utlization Study,
2023
  L:
A:
English
Clinical setting: hospital, Clinical setting: Primary care,
  Add to report
 
 
Assessing definitions and incentives adopted for innovation for pharmaceutical products in five high-income countries: a systematic literature review
Author(s): Naohiko Wakutsu 1, Emi Hirose 2, Naohiro Yonemoto 3, Sven Demiya 4 (rwesheorj 4)
Affiliations(s): 1) Graduate School of Economics, Nagoya City University, Nagoya, Japan 2) Health & Value, Pfizer Japan Inc., Tokyo, Japan. emi.hirose@pfizer.com 3) Health & Value, Pfizer Japan Inc., Tokyo, Japan 4) IQVIA Solutions Japan K.K., Tokyo, Japan
Publication(s):  Pharmaceutical Medicine
Document Type(s): Article,
Countries: France, Germany, Japan, UK, USA,
Click here for the abstract
C:
Y:
Miscellaneous,
2023
  L:
A:
English
Literature Review,
  Add to report
 
 
Overview of the European post-authorisation study register post-authorization studies performed in Europe from September 2010 to December 2018
Author(s): Janet Sultana 1 2, Salvatore Crisafulli 3, Mariana Almas 4, Ippazio Cosimo Antonazzo 5 6, Esme Baan 7, Claudia Bartolini 6, Maria Paola Bertuccio 3, Fedele Bonifazi 8 9, Annalisa Capuano 10 11, Antonella Didio 8 9, Vera Ehrenstein 12, Mariagrazia Felisi 8 13, Carmen Ferrajolo 10 11, Andrea Fontana 14, Remy Francisca 7, Annie Fourrier-Reglat 15, Joan Fortuny 16, Rosa Gini 6, Giulia Hyeraci 6, Christel Hoeve 7, Christos Kontogiorgis 17, Valentina Isgrò 18, Panagiotis-Nikolaos Lalagkas 17, Luca L'Abbate 18, Deborah Layton 19, Annalisa Landi 8 9, Silvia Narduzzi 19, Leonardo Roque Pereira 20, Georgios Poulentzas 17, Concetta Rafaniello 10 11, Giuseppe Roberto 6, Giulia Scondotto 3, Liberata Sportiello 10 11, Maddalena Toma 8 9, Massoud Toussi 19, Katia Verhamme 7, Elisabetta Volpe 8 9, Gianluca Trifirò 18,
Affiliations(s): Pharmacy Department, Mater Dei Hospital, Msida, Malta. 2Exeter College of Medicine and Health, Exeter, UK. 3Department of Medicine, University of Verona, Verona, Italy. 4Real World Solutions Department, IQVIA, Lisbon, Portugal. 5Research Centre on Public Health (CESP), University of Milan-Bicocca, Milan, Italy. 6Agenzia Regionale di Sanità della Toscana, Florence, Italy. 7Department of Medical Informatics, Erasmus Medical Centre, Rotterdam, The Netherlands. 8TEDDY European Network of Excellence for Paediatric Clinical Research, Pavia, Italy. 9Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus, Bari, Italy. 10Department of Experimental Medicine, University of Campania "Vanvitelli", Naples, Italy. 11Campania Regional Center of Pharmacovigilance and Pharmacoepidemiology, Naples, Italy. 12Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark. 13CVBF Consorzio per Valutazioni Biologiche e Farmacologiche, Pavia, Italy. 14Unit of Biostatistics, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy. 15Univ. Bordeaux, INSERM, Bordeaux Population Health Research Center, Team of Pharmacoepidemiology, UMR 1219, Bordeaux, France. 16RTI Health Solutions, Barcelona, Spain. 17Democritus University of Thrace, Alexandroupolis, Greece. 18Department of Diagnostics and Public Health, University of Verona, Verona, Italy. 19Data Science Hub, Real World Solutions, IQVIA, London, UK. 20Department of Datascience & Biostatistics, University Medical Center Utrecht, Utrecht, The Netherlands.
Publication(s):  Pharmacoepidemiol Drug Saf . 2022 Jun;31(6):689-705. doi: 10.1002/pds.5413. Epub 2022 Feb 11.
Document Type(s): Article,
Countries: Denmark, France, Italy, Netherlands, Portugal, Spain, UK,
Click here for the abstract
C:
Y:
Drug safety, Drug Utlization Study,
2022
  L:
A:
English
Database Study, Review,
  Add to report
 
 
Healthcare resource utilization and quality of life in patients with sarcoidosis-associated pulmonary hypertension
Author(s): Allan Lawrie1,2|Neil Hamilton3|Steven Wood2,4|Fernando Exposto5|Ruvimbo Muzwidzwa5|Louise Raiteri5|Amélie Beaudet6|Audrey Muller6|Rafael Sauter6|Nadia Pillai6|David G. Kiel
Affiliations(s): 1National Heart and Lung Institute,Imperial College London, London, UK2Insigneo Institute for In?Silico Medicine,University of Sheffield, Sheffield, UK3Sheffield Pulmonary Vascular DiseaseUnit, Sheffield Teaching Hospitals NHSFoundation Trust, Royal HallamshireHospital, Sheffield, UK4Scientific Computing, Sheffield TeachingHospitals NHS Foundation Trust, RoyalHallamshire Hospital, Sheffield, UK5IQVIA, London, UK6Actelion Pharmaceuticals Ltd.,Allschwil, Switzerland7Department of Infection, Immunity andCardiovascular Disease, University ofSheffield, Sheffield, UK
Publication(s):  Pulmonary Circulation. 2022;12:e12136.wileyonlinelibrary.com/journal/pul2|1of10https://doi.org/10.1002/pul2.12136
Document Type(s): Article,
Countries: Switzerland, UK,
Click here for the abstract
C:
Y:
Cardiovascular disease, Respiratory disease,
2022
  L:
A:
English
Observational study, Retrospective cohort analysis,
  Add to report
 
 
Protocol of the Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research (CHARIOT): Prospective Readiness cOhort (PRO) SubStudy
Author(s): Udeh-Momoh CT, Watermeyer T, Price G, de Jager Loots CA, Reglinska-Matveyev N, Ropacki M, Ketter N, Fogle M, Raghavan N, Arrighi M, Brashear R, Di J, Baker S, Giannakopoulou P, Robb C, Bassil D, Cohn M, McLellan-Young H, Crispin J, Lakey K, Lisa C, Chowdary Seemulamoodi Y, Kafetsouli D, Perera D, Car J, Majeed A, Ward H, Ritchie K, Perneczky R, Kivipelto M, Scott D, Bracoud L, Saad Z, Novak G, Ritchie CW, Middleton L
Affiliations(s): Imperial College London
Publication(s):  BMJ Open
Document Type(s): Article,
Countries: UK,
Click here for the abstract
C:
Y:
Neurological disorders,
2021
  L:
A:
English
Epidemiological study, Observational study,
  Add to report
 
 
Clinical and Economic Burden of Mild-to-Moderate Atopic Dermatitis in the UK: A Propensity-Score-Matched Case-Control Study
Author(s): Farah Toron 1, Maureen P Neary 2, Timothy W Smith 3, David Gruben 4, William Romero 5, Amy Cha 3, Keyur Patel 1, Simona Z Vasileva 6, Mahreen Ameen 7
Affiliations(s): 1Health Economics and Outcomes Research, Real World Solutions, IQVIA, 210 Pentonville Road, London, N1 9JY, UK. 2Inflammation & Immunology, Pfizer Inc, Collegeville, Pennsylvania, USA. 3Inflammation & Immunology, Pfizer Inc, New York, New York, USA. 4Global Biometrics and Data Management (Statistics), Pfizer Inc, Groton, Connecticut, USA. 5Inflammation & Immunology, Pfizer Ltd, Surrey, UK. 6Health Economics and Outcomes Research, Real World Solutions, IQVIA, 210 Pentonville Road, London, N1 9JY, UK. simona.vasileva@iqvia.com. 7Royal Free London National Health Services Foundation Trust, London, UK.
Publication(s):  PMID: 33846907 PMCID: PMC8163940 DOI: 10.1007/s13555-021-00519-7
Document Type(s): Article,
Countries: UK,
Click here for the abstract
C:
Y:
Dermatology, Drug Utlization Study, Methodology,
2021
  L:
A:
English
direct to patient research, direct-to-patient research, Economic evaluation, Population Based Study, Retrospective database analysis,
  Add to report
 
 
Identification of potentially undiagnosed patients with nontuberculous mycobacterial lung disease using machine learning applied to primary care data in the UK
Author(s): Orla M Doyle 1 2, Roald van der Laan 3 2, Marko Obradovic 4 2, Peter McMahon 5, Flora Daniels 6, Ashley Pitcher 7, Michael R Loebinger 8
Affiliations(s): Predictive Analytics, Real World Analytical Solutions, IQVIA, London, UK. 2These authors contributed equally. 3Insmed Utrecht, Utrecht, The Netherlands. 4Insmed Utrecht, Utrecht, The Netherlands marko.obradovic@insmed.com. 5Real-World Insights, IQVIA, London, UK. 6Real-World Insights, IQVIA, Basel, Switzerland. 7Real-World Insights, IQVIA, Copenhagen, Denmark. 8Royal Brompton and Harefield NHS Foundation Trust and Imperial College London, London, UK.
Publication(s):  PMID: 32430411 DOI: 10.1183/13993003.00045-2020
Document Type(s): Article,
Countries: Switzerland, UK,
Click here for the abstract
C:
Y:
Database Validity and methodology, Pain,
2021
  L:
A:
English
Population Based Study, Real World Evidence, Retrospective database analysis,
  Add to report
 
 
Incorporating patient generated health data into pharmacoepidemiological research. Pharmacoepidemiology and Drug Safety.
Author(s): Alison Bourke 1, William G Dixon 2, Andrew Roddam 3, Kueiyu Joshua Lin 4, Gillian C Hall 5, Jeffrey R Curtis 6, Sabine N van der Veer 7, Montse Soriano-Gabarró 8, Juliane K Mills 9, Jacqueline M Major 10, Thomas Verstraeten 11, Matthew J Francis 12, Dorothee B Bartels 13
Affiliations(s): 1Real World Solutions, IQVIA, London, UK. 2Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, UK. 3Data & Computational Sciences, GSK, London, UK. 4Brigham and Women's & Department of Medicine, Boston, Massachusetts, USA. 5Gillian Hall Epidemiology Ltd, London, UK. 6Division of Clinical Immunology & Rheumatology, The University of Birmingham, Birmingham, Alabama, USA. 7Centre for Health Informatics, Division of Informatics, Imaging and Data Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK. 8Bayer AG, Berlin, Germany. 9PRA Health Sciences, Raleigh, North Carolina, USA. 10Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA. 11P95 Pharmacovigilance and Epidemiology, Leuven, Belgium. 12The Procter & Gamble Company, Cincinnati, Ohio, USA. 13UCB Pharma, Anderlecht, Belgium.
Publication(s):  Pharmacoepidemiol Drug Saf . 2020 Dec;29(12):1540-1549. doi: 10.1002/pds.5169. Epub 2020 Nov 13.
Document Type(s): Article,
Countries: Belgium, Germany, UK, USA,
Click here for the abstract
C:
Y:
Database Validity and methodology, Health status & patient reported outcomes, Patient Registries & Real-World Study Methods,
2021
  L:
A:
English
Patient questionnaire, Review,
  Add to report
 
 
Access to palivizumab among children at high risk of respiratory syncytial virus complications in English hospitals
Author(s): Ania Zylbersztejn 1, Ofran Almossawi 1, Nikesh Gudka 2, Daniel Tompsett 1, Bianca De Stavola 1, Joseph F Standing 3, Rosalind Smyth 3, Pia Hardelid 1
Affiliations(s): 1Population, Policy & Practice Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, London, UK. 2Great Ormond Street Hospital, London, UK. 3Infection, Immunity and Inflammation Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, London, UK.
Publication(s):  Br J Clin Pharmacol . 2022 Mar;88(3):1246-1257. doi: 10.1111/bcp.15069. Epub 2021 Oct 7.
Document Type(s): Article,
Countries: UK,
C:
Y:
Infectious disease, Pediatrics, Respiratory disease,
2021
  L:
A:
English
Clinical setting: Primary care, Cost analysis, Database Study, direct to patient research, Population Based Study,
  Add to report
 
 
Burden of pulmonary arterial hypertension in England: retrospective HES database analysis
Author(s): Fernando Exposto 1, Ruben Hermans 2, Åsa Nordgren 2, Luke Taylor 2, Sanam Sikander Rehman 2, Robert Ogley 2, Evan Davies 3, Amina Yesufu-Udechuku 4, Amélie Beaudet
Affiliations(s): IQVIA, 210 Pentonville Road, London, N1 9JY, UK. 2IQVIA, London, UK. 3Actelion Pharmaceuticals Ltd, Allschwil, Basel-Landschaft, Switzerland. 4Actelion Pharmaceuticals UK Ltd, High Wycombe, UK.
Publication(s):  Ther Adv Respir Dis. 2021 Jan-Dec; 15: 1753466621995040. Published online 2021 Feb 23. doi: 10.1177/1753466621995040
Document Type(s): Article,
Countries: Switzerland, UK,
Click here for the abstract
C:
Y:
Cardiovascular disease, Respiratory disease,
2021
  L:
A:
English
Burden of illness,
  Add to report
 
 
 1 of 107 Next Page Last Page